Ligand Pharmaceuticals director sells $93k in stock

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices jump over 3% as Middle East war escalates, fuels supply fears Iran conflict latest: Hegseth says Iran conflict has "only just begun" Gold prices rebound from previous session’s hefty drop, helped by weaker dollar Nasdaq ends more than 1% higher as solid economic data lifts spirits (South Africa Philippines Nigeria) Ligand Pharmaceuticals director sells $93k in stock By Insider Trading Published 03/04/2026, 11:02 PM Ligand Pharmaceuticals director sells $93k in stock 0 LGND 2.31% Director John W. Kozarich of Ligand Pharmaceuticals Inc (NASDAQ:LGND) sold 467 shares of common stock on March 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed in multiple transactions with prices ranging from $197.1397 to $203.57, resulting in a total transaction value of $93,632. The stock has since climbed to $208.95, trading near its 52-week high of $212.49 following an 81% surge over the past year. The filing indicates that following the transactions, Kozarich directly owns 42,720 shares of Ligand Pharmaceuticals. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain price targets ranging from $220 to $277. The sales were executed pursuant to a written trading plan adopted by Kozarich on March 7, 2025, in accordance with Rule 10b5-1. In other recent news, Ligand Pharmaceuticals reported its fourth-quarter earnings for 2025, surpassing analyst expectations with an earnings per share of $2.02, compared to a forecast of $1.49. The company also exceeded revenue predictions, reporting $59.7 million against the anticipated $55.6 million. For the full year, Ligand achieved revenue of $268 million, with core revenue reaching $240 million and full-year adjusted EPS totaling $8.13. Oppenheimer raised its price target for Ligand shares to $277 from $275, maintaining an Outperform rating, citing the c...